Indian Journal of Cancer Home 

ORIGINAL ARTICLE
[View FULLTEXT] [Download PDF]
Year : 2017  |  Volume : 54  |  Issue : 3  |  Page : 535--538

Comparative pharmacokinetics, efficacy, and safety of bevacizumab biosimilar to reference bevacizumab in patients with metastatic colorectal cancer

Prasad Dattatray Apsangikar1, Sunil Ramdev Chaudhry1, Manoj Murlidhar Naik1, Shashank Babarao Deoghare2, Jamila Joseph2 
1 Medical Affairs Group, Reliance Life Sciences, Navi Mumbai, Maharashtra, India
2 Clinical Research Group, Reliance Life Sciences, Navi Mumbai, Maharashtra, India

Correspondence Address:
Dr. Prasad Dattatray Apsangikar
Medical Affairs Group, Reliance Life Sciences, Navi Mumbai, Maharashtra
India

OBJECTIVE: To establish clinical biosimilarity of BevaciRel™ bevacizumab biosimilar (study bevacizumab) with the reference innovator bevacizumab in terms of pharmacokinetics, efficacy, and safety in metastatic colorectal cancer (mCRC). MATERIALS AND METHODS: A total of 119 patients with mCRC were enrolled across 20 centers and randomized to receive study and reference bevacizumab in this Phase III clinical study. Of these, 116 patients were administered bevacizumab 5 mg/kg intravenously every 2 weeks with folinic acid, fluorouracil, and irinotecan regimen. The primary endpoint of the study was objective response rate (ORR) at week 25, and the secondary endpoints assessed were progression-free survival (PFS), overall survival (OS), and assessment of pharmacokinetics and safety along with immunogenicity in both treatment arms. RESULTS: The ORR was 60.53% in study bevacizumab and 66.67% in reference arm. The proportions of subjects showing CR and PR were comparable in both the arms. The median PFS at 1 year was 3.83 months in test arm and 4.6 months in reference arm. The mean OS was 10.91 months in test arm and 14.68 months in reference arm. The difference in ORR, median PFS, and OS was not statistically significant (P > 0.05). The median Tmaxwas 6.00 h in both the arms. The median t½ was 330.63 h and 226.14 h, respectively, for test and reference bevacizumab. The adverse event profile of both products was in line with the known profile of bevacizumab. CONCLUSION: The study biosimilar bevacizumab was found to be noninferior and clinically biosimilar to the reference bevacizumab, thereby meeting an unmet medical alternative need in mCRC.


How to cite this article:
Apsangikar PD, Chaudhry SR, Naik MM, Deoghare SB, Joseph J. Comparative pharmacokinetics, efficacy, and safety of bevacizumab biosimilar to reference bevacizumab in patients with metastatic colorectal cancer.Indian J Cancer 2017;54:535-538


How to cite this URL:
Apsangikar PD, Chaudhry SR, Naik MM, Deoghare SB, Joseph J. Comparative pharmacokinetics, efficacy, and safety of bevacizumab biosimilar to reference bevacizumab in patients with metastatic colorectal cancer. Indian J Cancer [serial online] 2017 [cited 2020 Sep 27 ];54:535-538
Available from: http://www.indianjcancer.com/article.asp?issn=0019-509X;year=2017;volume=54;issue=3;spage=535;epage=538;aulast=Apsangikar;type=0